The OSUCCC – James is one of 52 NCI-designated Comprehensive Cancer Centers and has been ranked as “exceptional” – the NCI’s highest descriptor – following each of its last three reviews for five-year re-designation as a CCC. It also is one of only a few centers that are funded by the NCI to conduct phase I, II and III clinical trials on novel anticancer drugs provided by the NCI.
In addition, the OSUCCC – James is ranked among America’s Best Hospitals for cancer care by U.S. News & World Report and has achieved Magnet® designation, the highest honor an organization can receive for quality patient care and professional nursing practice. With 21 floors, more than 1.1 million square feet and 356 beds, the OSUCCC – James is a transformational facility that fosters collaboration and integration of cancer research and clinical care. The OSUCCC – James strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a mission that leads to better methods of prevention, detection and treatment
Research grant funding
The OSUCCC – James has nearly 360 full or introductory cancer researchers who collectively represent 11 of the 15 colleges at Ohio State. Each researcher is in one of five multidisciplinary research programs: Cancer Control (CC); Leukemia Research (LR); Cancer Biology (CB); Molecular Carcinogenesis and Chemoprevention (MCC); or Translational Therapeutics (TT). In 2021, OSUCCC – James researchers received 28 new research grants totaling $11.1 million from the NCI, bringing the cancer program’s annual total NCI grant funding to $55.3 million. The OSUCCC – James ranks 19th among cancer institutions in the United States for total NCI funding.
Research publications
In 2021, cancer researchers at the OSUCCC – James authored or co-authored 824 publications in peer-reviewed journals, including 174 that appeared in journals with impact factors of 10.0 or higher. Also, 98.3% of all articles published were collaborative, and 96.7% of the publications were multiinstitutional.
Patient care
In calendar year (CY) 2021, the OSUCCC – James had an average daily occupancy rate of 91.9% and an average daily census of 308.5 inpatients. The total number of inpatient admissions for CY 2021 was 15,039. Also in CY 2021, the institution received 731,570 outpatient visits, which included 693,780 in-person and 37,790 virtual visits via telehealth.
Clinical trials
Patients at the OSUCCC – James have access to hundreds of clinical trials offering sophisticated treatments, including some that are available nowhere else. In calendar year (CY) 2021, researchers at the OSUCCC – James opened 182 clinical trials to bring the total number of available trials to 687, of which 540 are interventional. The CY 2021 accrual rate for therapeutic trials at the OSUCCC – James was 14%. The five-year average patient accrual to therapeutic clinical trials here is 15% – well above the national rate of about 3%.
Total Cancer Care® protocol
Since 2014, the OSUCCC – James has enrolled nearly 63,000 patients for a 94% accrual rate in a Total Cancer Care® (TCC) protocol for voluntarily sharing de-identified clinical data that moves cancer research forward and personalizes cancer care. The TCC protocol helps clinicians understand differences among cancer patients and find ways to individualize prevention, detection and treatment.
ORIEN precision medicine collaboration
The TCC protocol referenced earlier has been adopted by all 18 member institutions across the nation that constitute the Oncology Research Information Exchange Network (ORIEN), a research collaboration co-founded and co-anchored by the OSUCCC – James and Moffitt Cancer Center in Tampa, Florida. Through ORIEN, more than 315,700 TCC-consented patients across the nation have agreed to donate their clinical data for research to help scientists understand cancer at the molecular level, making ORIEN one of the world’s largest precision medicine collaborations to address this disease.